Back to search

NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK

By Reinhard Angelmar,  Andrea Bieser
Published 07 Jan 2006
Reference 5381
Topic Marketing
Industry Pharmaceuticals
Region Europe
Length 31 page(s)
Inspection copy
Teaching note
6.00
Add to cart
Summary

NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient €10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.

Teaching objectives

Value pricing in the healthcare sector. Implications of value pricing for the main stakeholders (patients, physicians, payers, manufacturers). Implications of the adoption of cost effectiveness criteria by healthcare buyers for product development and international launch decisions of pharmaceutical companies.

Keywords
  • Pricing
  • Pharmaceuticals
  • Cost effectiveness
  • Technology assessment
  • HMI
  • Pharmaceutical and Medical Device Sectors
About the authors
Angelmar

Reinhard Angelmar

Emeritus Professor of Marketing

Andrea Bieser


Recommended Cases

Medicines for Malaria Venture: Accessing the Inaccessible

By  Prashant Yadav,  Luk Van Wassenhove,  Orla Stapleton
Add to cart
Malaria causes over 1 million deaths per year, 90% of which are preventable. Drug resistance has become one of the most important barriers to effective treatment. The cheapest and most widely-used drugs are ineffective in most countries. Medicines for Malaria Venture (MMV) was founded in 1999 with the goal of developing new artemisinin combination therapies (ACT) to effectively treat the disease.
    View case

    Patient Access to Pulmolive in China

    By  Reinhard Angelmar,  Ebru Tekin Turhan
    Add to cart
    An international pharmaceutical company must decide on the pricing and access strategy for the first targeted medicine approved in China to treat advanced non-small cell lung cancer, a high mortality condition, in ALK-positive patients.
      View case

      Patient Access to Rencell in China

      By  Reinhard Angelmar,  Ebru Tekin Turhan
      Add to cart
      Rencell is a targeted therapy against metastatic renal cell cancer, which significantly prolongs disease-free survival. However, Rencell's international wholesale price of $1,000 for one month of treatment makes the drug unaffordable for many patients in China.
        View case